[Surgical management of retroperitoneal soft-tissue sarcomas--an overview].
BACKGROUND
Retroperitoneal soft-tissue sarcomas (RSTS) represent a rare and heterogeneous class of diseases for which the clinical management is still largely non-standardised. Based on a selective review of recent publications, it was the purpose of the present review article to summarize the current concepts of disease classification, diagnostics and surgical as well as multimodal therapy for these tumors.


METHODS
A clinically based empirical review derived from a literature search focusing on publications from the past 5  years was carried out.


RESULTS
Due to the paucity of randomised-controlled trials, therapy for RSTS is largely based on personal experience, retrospectively gathered data and historical controls. Pre-therapeutic planning requires precise information on the localisation, extension, and texture of the tumor through cross-sectional imaging (CT, MRI) as well as histological diagnosis through percutaneous or open biopsy. Complete tumor resection is crucial. Recent studies have confirmed the importance of microscopically negative resection margins which has subsequently led to a trend towards more radical resection. Chemotherapy does not play a role in the adjuvant setting except in clinical trials; however, radiotherapy has been controversely debated in adjuvant RSTS therapy. Efforts to limit radiation toxicity include modern techniques as well as a strategy of using pre-resection radiotherapy instead of postoperative radiation. Surgery is also the treatment of choice for locally recurrent RSTS and pulmonary metastases. The prognosis of RSTS depends on the quality of surgical care and several disease-specific factors (histological type, grading).


CONCLUSIONS
The clinical management of RSTS is complex and can only partly be considered as evidence-based. Due to the required level of experience in the treatment of these tumor lesions and the involvement of several subspecialties, pre-therapeutic planning, treatment and follow-up should be limited to high-volume surgical centres. In order to achieve microscopically negative resection margins, multivisceral resections are a valuable option after thorough consideration of the risks and benefits. Adjuvant radiotherapy needs to be decided upon on an individual basis, taking into account patient- and tumor-specific factors as well as resection status.
Garlipp
B
B
Universitätsklinikum Magdeburg, Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Magdeburg, Deutschland. benjamin.garlipp@med.ovgu.de
Schulz
H-U
HU
Zeile
M
M
Lippert
H
H
Meyer
F
F
D001706:Biopsy; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D006801:Humans; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012186:Retroperitoneal Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D012509:Sarcoma / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D014057:Tomography, X-Ray Computed